Post IPO investors in DACH
Updated 16 Nov 2026
Venture funds
2 funds, by portfolio companies funded in the last 12 months| # | Fund | Sectors | Stages | Leads | Funded, 12 months |
|---|---|---|---|---|---|
| 1 | Nextech Invest Nextech Invest is a venture capital and private equity firm spanning early to emerging growth stages, with recent companies Circle Pharma and Atavistik Bio. Zürich, Switzerland |
Health care, Biotech | Early stage venture, Late stage venture | 31% | 2 |
| 2 | Novartis Venture Fund Novartis Venture Fund focuses on novel therapeutics and platforms, with recent investments in Hepalink and FoRx Therapeutics. Basel, Switzerland |
Health care, Biotech | Seed, Early stage venture, Late stage venture | 27% | 2 |
Table 1. Post IPO investors in DACH: venture capital and micro VC funds ranked by companies whose most recent round closed in the last 12 months. Leads is the share of all recorded investments where the fund was lead investor. Source: FundingWatcher. Data as of 16 November 2026.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Investor | Type | Location | Phone | |
|---|---|---|---|---|
| Deutsche Bank | Investment bank | Frankfurt, Germany | •••@db.com | +49 69••• |
| Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | •••@sosei.com | 877 28••• |
| HBM Healthcare Investments | Venture capital firm | Zug, Switzerland | •••@hbmhealthcare.com | +41 41••• |
| Wellington Partners | Venture capital firm | Munich, Germany | •••@wellington-partners.com | +44 20••• |
| UBS | Corporate venture arm | Zürich, Switzerland | •••@ubs.com | 41 44 ••• |
| Rocket Internet | Startup incubator | Berlin, Germany | •••@rocket-internet.com | |
| VI Partners | Venture capital firm | Altendorf, Switzerland | •••@vipartners.ch | +41 41••• |
| Nextech Invest | Venture capital firm | Zürich, Switzerland | •••@nextechinvest.com | 41 (0)••• |
8 rows of the CSV in 5 of its 15 columns, email and phone masked.
- 35 of the 55 post ipo investors in DACH have a published email address, 27 a phone number and 52 a website.
- Deutsche Bank has the most recorded investments, 304, 102 of them as lead investor.
- 12 of them are investors in at least one company that closed its most recent round in the last 12 months.
- UBS is an investor in 3 of those companies, more than any other investor on this list.
- The newest round among their portfolio companies is Circle Pharma's $92.5M Series E on 16 September 2026.
- Software is the most common sector across their 203 portfolio companies (62%).
- Early stage venture is the most common investment stage, recorded for 33 of them (60%).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Post IPO investors in DACH
30 of 55, most investments first| # | Investor | Type | Location | Invests in | Latest portfolio companies | Funded, 12 months | Investments | Lead | Exits | Phone | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Deutsche Bank | Investment bank | Frankfurt, Germany | Fintech, Artificial intelligence | Synthesized, Partior, Blueground | 304 | 102 | 132 | •••@db.com | +49 69••• | In the CSV | |
| 2 | Novartis Venture Fund | Corporate venture arm, Venture capital firm | Basel, Switzerland | Health care, Biotech | Hepalink, FoRx Therapeutics | 2 | 279 | 75 | 77 | •••@sosei.com | 877 28••• | |
| 3 | HBM Healthcare Investments | Venture capital firm | Zug, Switzerland | Biotech, Health care | 4TEEN4 Pharmaceuticals, Sphingotec GmbH, Odyssey Therapeutics | 260 | 47 | 90 | •••@hbmhealthcare.com | +41 41••• | ||
| 4 | Wellington Partners | Venture capital firm | Munich, Germany | Health care, Biotech | nyra health | 1 | 252 | 80 | 65 | •••@wellington-partners.com | +44 20••• | In the CSV |
| 5 | UBS | Corporate venture arm, Fund of funds | Zürich, Switzerland | Fintech, Hardware | SWISSto12, MerQube, Nasdaq Private Market | 3 | 157 | 53 | 53 | •••@ubs.com | 41 44 ••• | In the CSV |
| 6 | Rocket Internet | Startup incubator, Private equity firm | Berlin, Germany | Fintech, Commerce | enshift | 1 | 155 | 43 | 52 | •••@rocket-internet.com | In the CSV | |
| 7 | VI Partners | Venture capital firm | Altendorf, Switzerland | Health care, Biotech | L.E.S.S. | 1 | 111 | 26 | 22 | •••@vipartners.ch | +41 41••• | In the CSV |
| 8 | Nextech Invest | Venture capital firm | Zürich, Switzerland | Health care, Biotech | Circle Pharma, Atavistik Bio | 2 | 100 | 31 | 43 | •••@nextechinvest.com | 41 (0)••• | In the CSV |
| 9 | BASF Venture Capital | Corporate venture arm | Ludwigshafen, Germany | Biotech, Artificial intelligence | Computomics | 1 | 88 | 35 | 18 | 973 24••• | In the CSV | |
| 10 | responsAbility Investments AG | Fund of funds, Private equity firm | Zürich, Switzerland | Fintech, Commerce | Koa Switzerland, Investree, ePaylater | 74 | 42 | 11 | •••@responsability.com | +41 44••• | In the CSV | |
| 11 | Partners Group | Private equity firm | Baar, Switzerland | Hardware, Artificial intelligence | Neara, Akur8, Sirion | 74 | 39 | 34 | •••@partnersgroup.com | 212 90••• | In the CSV | |
| 12 | Monkfish Equity | Venture capital firm | Leipzig, Germany | Hardware, Artificial intelligence | Tractive, TopCheck, Pixsy | 53 | 6 | 18 | •••@monkfish-equity.com | +49 32••• | In the CSV | |
| 13 | Heliad AG | Private equity firm, Venture capital firm | Frankfurt, Germany | Fintech, Commerce | FINN | 1 | 46 | 25 | 9 | •••@heliad.com | +49 69••• | In the CSV |
| 14 | 3B Future Health Fund | Venture capital firm | Monaco, Germany | Biotech, Health care | Navion Neurosciences | 1 | 36 | 11 | 5 | •••@helsinn.com | +377 9••• | In the CSV |
| 15 | Barclays Bank | Investment bank | Hamburg, Germany | 35 | 14 | 22 | •••@barclays.de | 0800 1••• | In the CSV | |||
| 16 | dRx Capital | Corporate venture arm, Venture capital firm | Basel, Switzerland | Biotech, Health care | Dopavision | 31 | 4 | 8 | In the CSV | |||
| 17 | Pictet Private Equity Investors S.A. | Investment bank | Geneva, Switzerland | Artificial intelligence, Biotech | Unique AI, Harbinger Health, Red Date Technology | 30 | 4 | 6 | •••@pictet.com | In the CSV | ||
| 18 | Nice & Green SA | Investment bank, Private equity firm | Nyon, Switzerland | 29 | 26 | 20 | •••@nicengreen.ch | In the CSV | ||||
| 19 | ABACON | Fund of funds, Hedge fund | Hamburg, Germany | Artificial intelligence, Energy | Entrix | 1 | 28 | 4 | 7 | •••@abacon.capital | In the CSV | |
| 20 | TVM Capital Life Science | Venture capital firm | Munich, Germany | Health care, Biotech | leon nanodrugs, Smart Reporting, Myo | 25 | 17 | 4 | •••@tvm-capital.com | +49899••• | In the CSV | |
| 21 | Armada Investment AG | Family office, Private equity firm | Kusnacht, Switzerland | Energy, Fintech | Last Energy | 1 | 19 | 5 | 5 | •••@armada.com | +41 44••• | In the CSV |
| 22 | Allianz Global Investors | Private equity firm | Munich, Germany | 17 | 6 | 6 | •••@allianzgi.de | +49 92••• | In the CSV | |||
| 23 | kineo finance | Venture debt fund | Basel, Switzerland | 15 | 7 | 0 | In the CSV | |||||
| 24 | Egora Holding | Venture capital firm | Martinsried, Germany | 13 | 5 | 3 | •••@egoraholding.com | +49 (0••• | In the CSV | |||
| 25 | Oesterreichische Entwicklungsbank AG | Investment bank | Vienna, Austria | 12 | 6 | 5 | +43 1 ••• | In the CSV | ||||
| 26 | Kliwla Family Office | Family office, Hedge fund | Vaduz, Liechtenstein | 9 | 0 | 3 | •••@kliwla.com | |||||
| 27 | New Energy Capital | Private equity firm | Hanover, Germany | 8 | 5 | 2 | •••@newenergycapital.com | 603.64••• | In the CSV | |||
| 28 | Obotritia Capital | Private equity firm, Venture capital firm | Potsdam, Germany | Fintech | Arrago | 1 | 7 | 3 | 1 | •••@obocap.com | +49 (0••• | In the CSV |
| 29 | BayernLB Capital Partner | Venture capital firm | Munich, Germany | 6 | 2 | 3 | •••@bayernlb-cp.de | |||||
| 30 | DDM Group | Private equity firm | Baar, Switzerland | ClimateCamp | 5 | 3 | 2 | +41417••• | In the CSV |
Table 2. Post IPO investors in DACH: the first 30 by recorded investments with a website and a location. Email and phone are masked here and complete in the CSV. Source: FundingWatcher. Data as of 16 November 2026. Base: 55.
Most active in the last 12 months
By portfolio companies funded| # | Investor | Location | Funded, 12 months | Portfolio | Latest |
|---|---|---|---|---|---|
| 1 | UBS | Zürich, Switzerland | 3 | 26 | SWISSto12, MerQube, Nasdaq Private Market |
| 2 | Nextech Invest | Zürich, Switzerland | 2 | 5 | Circle Pharma, Atavistik Bio |
| 3 | Novartis Venture Fund | Basel, Switzerland | 2 | 20 | Hepalink, FoRx Therapeutics |
| 4 | 3B Future Health Fund | Monaco, Germany | 1 | 2 | Navion Neurosciences |
| 5 | BASF Venture Capital | Ludwigshafen, Germany | 1 | 8 | Computomics |
| 6 | Heliad AG | Frankfurt, Germany | 1 | 4 | FINN |
| 7 | ABACON | Hamburg, Germany | 1 | 5 | Entrix |
| 8 | VI Partners | Altendorf, Switzerland | 1 | 19 | L.E.S.S. |
| 9 | Wellington Partners | Munich, Germany | 1 | 36 | nyra health |
| 10 | Armada Investment AG | Kusnacht, Switzerland | 1 | 2 | Last Energy |
| 11 | Obotritia Capital | Potsdam, Germany | 1 | 2 | Arrago |
| 12 | Rocket Internet | Berlin, Germany | 1 | 21 | enshift |
Table 3. Post IPO investors in DACH: investors in the most companies whose most recent round falls in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Latest rounds in their portfolios
Newest first| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors on this list | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Circle Pharma | Circle Pharma develops bioavailable macrocyclic peptide therapeutics that target protein-protein interactions. | Biotech | South San Francisco, United States | Series E | $92.5M | 2026-09-16 | $300.0M | Nextech Invest | 11 to 50 | 2012 |
| Navion Neurosciences | Navion Neurosciences develops sodium channel therapeutics for neurological diseases at a pre-clinical stage. | Artificial intelligence | Charlottesville, United States | Seed | $10.8M | 2026-09-09 | $21.2M | 3B Future Health Fund | 1 to 10 | 2021 |
| Computomics | Computomics applies artificial intelligence to genomics data to advance agricultural solutions. | Artificial intelligence | Tübingen, Germany | Series B | $7.3M | 2026-08-18 | $10.0M | BASF Venture Capital | 11 to 50 | 2012 |
| SWISSto12 | SWISSto12 designs, manufactures, and integrates radio frequency products for commercial and government customers. | Hardware | Renens, Switzerland | Series C | $70.0M | 2026-07-16 | $202.3M | UBS | 251 to 500 | 2011 |
| FINN | FINN offers car subscriptions that let you drive vehicles without long-term purchase or lease commitments. | Commerce | Munich, Germany | Series D | $113.4M | 2026-06-24 | $2.2B | Heliad AG | 251 to 500 | 2019 |
| MerQube | MerQube provides technology for rules-based investment strategies and passive index design. | Fintech | San Francisco, United States | Series C | $30.0M | 2026-04-13 | $67.0M | UBS | 51 to 100 | 2019 |
| Entrix | Entrix provides software and services for operating energy storage and renewable energy assets. | Artificial intelligence | Munich, Germany | Series B | $49.9M | 2026-03-25 | $74.8M | ABACON | 101 to 250 | 2021 |
| Atavistik Bio | Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. | Biotech | Cambridge, United States | Series B | $40.0M | 2026-03-05 | $260.0M | Nextech Invest | 11 to 50 | 2021 |
| nyra health | Nyra Health offers an AI and evidence-based neurological research tablet app for therapy. | Artificial intelligence | Vienna, Austria | Series A | $23.6M | 2026-02-24 | $28.5M | Wellington Partners | 11 to 50 | 2020 |
| Nasdaq Private Market | Nasdaq Private Market provides a marketplace where private companies, banks, brokers, and investors transact. | Fintech | San Francisco, United States | Series C | $37.6M | 2026-01-16 | $143.9M | UBS | 51 to 100 | 2013 |
Table 4. Post IPO investors in DACH: the 10 most recent rounds of companies they back. Source: FundingWatcher. Data as of 16 November 2026.
Portfolio sectors
| Portfolio sectors | Companies | Share |
|---|---|---|
| Software | 126 | 62% |
| Health care | 53 | 26% |
| Fintech | 52 | 26% |
| Biotech | 43 | 21% |
| Artificial intelligence | 36 | 18% |
| Hardware | 31 | 15% |
| Commerce | 16 | 8% |
| Cybersecurity | 8 | 4% |
| Energy | 5 | 2% |
| Education | 4 | 2% |
Table 5. Post IPO investors in DACH: portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Investment stages
| Investment stages | Investors | Share |
|---|---|---|
| Post IPO investors | 55 | 100% |
| Early stage investors | 33 | 60% |
| Late stage investors | 31 | 56% |
| Private equity investors | 27 | 49% |
| Venture investors | 27 | 49% |
| Seed investors | 26 | 47% |
| Debt investors | 23 | 42% |
| Convertible note investors | 11 | 20% |
Table 6. Post IPO investors in DACH by stage they invest at. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Investors | Share |
|---|---|---|
| Switzerland | 26 | 47% |
| Germany | 25 | 45% |
| Austria | 2 | 4% |
| Liechtenstein | 2 | 4% |
Table 7. Post IPO investors in DACH by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Investors | Share |
|---|---|---|
| Munich | 6 | 11% |
| Berlin | 6 | 11% |
| Frankfurt | 5 | 9% |
| Zürich | 5 | 9% |
| Basel | 4 | 7% |
| Geneva | 4 | 7% |
| Baar | 2 | 4% |
| Hamburg | 2 | 4% |
| Vienna | 2 | 4% |
| Vaduz | 2 | 4% |
| Zug | 1 | 2% |
| Altendorf | 1 | 2% |
Table 8. Post IPO investors in DACH by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Founded
| Founded | Investors | Share |
|---|---|---|
| 2020s | 3 | 7% |
| 2010s | 9 | 20% |
| 2000s | 19 | 42% |
| 1990s | 6 | 13% |
| 1980s | 1 | 2% |
| 1960s | 2 | 4% |
Table 9. Post IPO investors in DACH by founding decade. Source: FundingWatcher. Data as of 16 November 2026.
Method
- An investor is on this list when its recorded investment stages include post ipo investors and its headquarters is in DACH. On 16 November 2026 that is 55 investors.
- 35 rows carry an email address and 27 a phone number from the investor file. Investments, lead investments and exits are the counts the source records.
- The table prints the first 30 rows by recorded investments that carry a website and a location, with email and phone masked. The CSV carries all 55 rows: 3 have no website and 0 no location.
Sources, fields and exclusions of both files: Method.
Questions
- How many post ipo investors in DACH are on the list?
- 55, in the file dated 16 November 2026. 12 of them invested in a company whose most recent round falls in the last 12 months.
- How many have an email address?
- 35 of the 55 carry an email address in the download and 27 a phone number.
- What does the CSV contain?
- One row per investor, 15 columns: name, types, stages, city, region, country, founded, website, linkedin, investments, funded_last_12m, exits, lead_investments, email, phone.
- How much does the list cost?
- $29 one-time for all 55 rows, no account. Every investor and every startup, two files, cost $99. With partner contacts, up to 2 per firm compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV with 55 rows, 35 firm email addresses and 27 phone numbers, on the page after payment and by mail. The emails are the address a firm publishes: 22 of the 35 are inboxes such as info@ or contact@. No partner names.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.